UNITED STATES SECURITIES AND EXCHANGE COMMISSION July 24, 2008

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

SGX Pharmaceuticals, Inc.

File No. 333-128059 - CF#22252

SGX Pharmaceuticals, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 filed on September 2, 2005, as amended.

Based on representations by SGX Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.23	through August 1, 2013
Exhibit 10.25	through August 1, 2013
Exhibit 10.29	through July 1, 2013

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Patti J. Dennis Chief, Office of Disclosure Support